Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Head and Neck Neoplasms
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 20 years and 125 years
- Gender
- Both males and females
Description
It is a single arm, phase II, single center, prospective, open label clinical trial.
It is a single arm, phase II, single center, prospective, open label clinical trial.
Tracking Information
- NCT #
- NCT03695510
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Ruey-Long Hong, MD PhD Department of Oncology, National Taiwan University Hospital
Get Well Soon